Most Read Articles
Tristan Manalac, 09 Sep 2018
Structured and remote patient management interventions are effective in reducing all-cause mortality and the number of days lost due to unplanned hospitalizations in heart failure patients, according to a recent study.
Radha Chitale, 08 Apr 2016
A trial assessing the implantable CardioFit® device designed to stimulate the parasympathetic nervous system in heart failure patients failed to meet its primary endpoints – reducing the rate of hospitalization due to heart failure or death by any cause.
27 Aug 2018
Obese men appear to have better ST-elevation myocardial infarction (STEMI) prognoses than their normal weight counterparts, regardless of metabolic syndrome status, a recent study has shown.
Stephen Padilla, 04 Sep 2018
The prevalence of individuals with hypertension is expected to rise significantly with the implementation of the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) high blood pressure guidelines, according to a study.

Sex steroids affect cardiovascular outcomes in transgender individuals

13 Nov 2017

Sex steroid therapy appears to elevate low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels and reduce high-density lipoprotein cholesterol (HDL-C) levels in female-to-male (FTM) individuals, while oral oestrogens appear to increase TG levels in male-to-female (MTF) individuals, suggests a study with low-quality evidence. Moreover, data on significant patient outcomes are still lacking.

Researchers conducted a comprehensive search of several databases up to 7 April 2015 for studies evaluating the effect of sex steroid use on lipids, myocardial infarction, stroke, venous thromboembolism (VTE) and mortality in transgender individuals. A random-effects model was used to pool weighted mean differences and 95 percent confidence intervals (CIs).

A total of 29 studies with moderate risk of bias met the inclusion criteria. Sex steroid in FTM individuals correlated with statistically significant increases in serum TG levels at 3 to 6 months and at ≥24 months (21.4 mg/dL; 95 percent CI, 0.14 to 42.6) and in LDL-C levels at 12 and ≥24 months (17.8 mg/dL; 3.5 to 32.1). There was a significant reduction in HDL-C levels across all follow-up periods (highest at ≥24 months, −8.5 mg/dL; −13.0 to −3.9).

Serum TG levels were significantly greater in MTF individuals at ≥24 months (31.9 mg/dL; 3.9 to 59.9) without any changes in other parameters. There were few reports of myocardial infarction, stroke, VTE and death events, and these more frequently occurred among MTF individuals.

“Transgender individuals receive cross-sex hormonal therapy to induce desired secondary sexual characteristics despite limited data regarding its effects on cardiovascular health,” according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 09 Sep 2018
Structured and remote patient management interventions are effective in reducing all-cause mortality and the number of days lost due to unplanned hospitalizations in heart failure patients, according to a recent study.
Radha Chitale, 08 Apr 2016
A trial assessing the implantable CardioFit® device designed to stimulate the parasympathetic nervous system in heart failure patients failed to meet its primary endpoints – reducing the rate of hospitalization due to heart failure or death by any cause.
27 Aug 2018
Obese men appear to have better ST-elevation myocardial infarction (STEMI) prognoses than their normal weight counterparts, regardless of metabolic syndrome status, a recent study has shown.
Stephen Padilla, 04 Sep 2018
The prevalence of individuals with hypertension is expected to rise significantly with the implementation of the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) high blood pressure guidelines, according to a study.